5 completed, 1 active not recruiting, 1 terminated. 7 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 7 | Completed 5, Active not recruiting 1, Terminated 1 |
Follow Refractory Multiple Myeloma: new trials by email Literature Review of Refractory Multiple Myeloma trials Research Report on Refractory Multiple Myeloma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| TJ202, Lenalidomide and Dexamethasone vs. Lenalidomide and Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma TJ202, Lenalidomide and Dexamethasone, Lenalidomide and Dexamethasone - Multiple Myeloma in Relapse, Refractory Multiple Myeloma | Phase 3 | Completed | TJ Biopharma Co., Ltd. | 289 | 2019-03-27 | 2024-07-03 |
| Study of Carfilzomib, Daratumumab and Dexamethasone for Patients With Relapsed and/or Refractory Multiple Myeloma. Dexamethasone, Daratumumab, Carfilzomib - Relapsed Multiple Myeloma, Refractory Multiple Myeloma | Phase 3 | Completed | Amgen | 466 | 2017-06-13 | 2025-05-09 |
| A Phase 3 Study Comparing Oral Ixazomib Plus Lenalidomide and Dexamethasone Versus Placebo Plus Lenalidomide and Dexamethasone in Adult Participants With Relapsed and/or Refractory Multiple Myeloma Ixazomib, Lenalidomide, Dexamethasone - Relapsed Multiple Myeloma, Refractory Multiple Myeloma | Phase 3 | Completed | Takeda | 722 | 2012-08-01 | 2023-03-10 |
| Filgrastim With or Without Plerixafor in Treating Patients With Multiple Myeloma Previously Treated With Lenalidomide plerixafor, filgrastim - Refractory Multiple Myeloma | Phase 3 | Terminated | Case Comprehensive Cancer Center | 9 | 2011-07-01 | 2014-08-06 |
| Internet-Based Program With or Without Telephone-Based Problem-Solving Training in Helping Long-Term Survivors of Hematopoietic Stem Cell Transplant Cope With Late Complications internet-based intervention, questionnaire administration, psychosocial assessment and care - Accelerated Phase Chronic Myelogenous Leukemia, Adult Acute Lymphoblastic Leukemia in Remission | Phase 3 | Completed | Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium | 1337 | 2008-08-01 | 2012-03-07 |
| Melphalan and Amifostine Followed By One or Two Autologous or Syngeneic Stem Cell Transplants and Maintenance Therapy in Treating Patients With Stage II-III Multiple Myeloma melphalan, amifostine trihydrate, peripheral blood stem cell transplantation - Refractory Multiple Myeloma, Stage II Multiple Myeloma | Phase 3 | Completed | Fred Hutchinson Cancer Center | 130 | 2005-07-01 | 2015-08-21 |
| Lenalidomide in Treating Patients With Multiple Myeloma Undergoing Autologous Stem Cell Transplant Autologous Hematopoietic Stem Cell Transplantation, Laboratory Biomarker Analysis, Lenalidomide - DS Stage I Multiple Myeloma, DS Stage II Multiple Myeloma | Phase 3 | Active not recruiting | National Cancer Institute (NCI) | 460 | 2004-12-15 | 2026-08-26 |
Multiple Myeloma (7) · Blast Crisis (1) · Burkitt Lymphoma (1) · Congenital Abnormalities (1) · Depression (1) · Fatigue (1) · Hodgkin Disease (1) · Leukemia, Hairy Cell (1) · Leukemia, Lymphocytic, Chronic, B-Cell (1) · Leukemia, Myeloid, Accelerated Phase (1) · Leukemia, Myeloid, Acute (1) · Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative (1) · Leukemia, Myeloid, Chronic-Phase (1) · Leukemia, Myelomonocytic, Chronic (1) · Leukemia, Neutrophilic, Chronic (1)
Blood Protein Disorders (7) · Cardiovascular Diseases (7) · Hematologic Diseases (7) · Hemic and Lymphatic Diseases (7) · Hemorrhagic Disorders (7) · Hemostatic Disorders (7) · Immune System Diseases (7) · Immunoproliferative Disorders (7) · Lymphoproliferative Disorders (7) · Neoplasms (7) · Neoplasms by Histologic Type (7) · Neoplasms, Plasma Cell (7) · Paraproteinemias (7) · Vascular Diseases (7) · Behavior (1)
Dexamethasone (3) · Lenalidomide (3) · Melphalan (2) · Peripheral Blood Stem Cell Transplantation (2) · Amifostine (1) · Counseling (1) · Filgrastim (1) · Granulocyte Colony-Stimulating Factor (1) · In Situ Hybridization, Fluorescence (1) · Psychiatric Rehabilitation (1) · Stem Cell Transplantation (1) · Therapeutics (1) · carfilzomib (1) · daratumumab (1) · ixazomib (1)
Amgen (1) · Case Comprehensive Cancer Center (1) · Fred Hutchinson Cancer Center (1) · Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium (1) · National Cancer Institute (NCI) (1) · TJ Biopharma Co., Ltd. (1) · Takeda (1)
United States (6) · Canada (2) · Taiwan (2) · Australia (1) · Austria (1) · Belgium (1) · Bulgaria (1) · China (1) · Czechia (1) · France (1) · Greece (1) · Hungary (1) · Japan (1) · Poland (1) · Romania (1)
Hien Duong, MD (1) · Hillard Lazarus, MD (1) · Karen Syrjala (1) · Philip L McCarthy (1) · William Bensinger (1)
PMID 22571201, PMID 27002117, PMID 27119237, PMID 28683766, PMID 28751562, PMID 28803351, PMID 28826616, PMID 29054911, PMID 32145111, PMID 32628342, PMID 33420905, PMID 34111952, PMID 36282798, PMID 42822478
2016 (1), R01CA112631 (1), U10CA031946 (1), U10CA180821 (1)